The inhibitors of the SGLT2 carrier possess unambiguous CV pleiotropic benefits that go beyond solely anti-hyperglycemic properties, and this is supported by large RCTs involving different gliflozins in both diabetes mellitus and HF, independently of each other disease [251,252,253,254,255,256]. This evidence concerns the gene SLC5A2 and diabetes mellitus.